Targeting CXCR4 in HIV Cell-Entry Inhibition

Medicin og biovidenskab

• Acquired Immunodeficiency Syndrome 23%
• Biological Availability 25%
• Chemokine Receptors 31%
• Chemokines 79%
• Drug Discovery 28%
• HIV 77%
• HIV Infections 24%
• HIV-1 97%
• Human Herpesvirus 8 36%
• Ligands 19%
• N'-((1H-benzo(d)imidazol-2-yl)methyl)-N'-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine 58%
• Peptides 17%
• Peptoids 100%
• Pharmacokinetics 21%
• Phase II Clinical Trials 34%
• plerixafor octahydrochloride 40%
• Therapeutics 13%

Kemiske forbindelser

• Antagonist 78%
• Anti HIV 68%
• Bioavailability 27%
• Chemokine Receptor CXCR4 Antagonist 98%
• Drug 14%
• Ligand 12%
• Modification 15%
• Peptide 16%
• Pharmacokinetics 21%
• Strain 38%